Last reviewed · How we verify
PF-07329640 (pf-07329640)
Mechanism of action not disclosed in available data.
PF-07329640 is a Pfizer-developed oncology candidate that was discontinued during Phase 1 clinical development. The compound was being evaluated as a monotherapy in patients with advanced or metastatic solid tumors, including non-small cell lung cancer. No FDA label, mechanism of action details, or molecular target information is publicly available in the source data, limiting comprehensive characterization. The Phase 1 trial was terminated early with minimal enrollment (N=4), suggesting either safety concerns, lack of efficacy signals, or strategic portfolio decisions by Pfizer. Without published clinical data, peer-reviewed literature, or regulatory filings, the drug's commercial potential and scientific differentiation cannot be assessed. The discontinuation indicates this candidate did not advance to later-stage development.
At a glance
| Generic name | pf-07329640 |
|---|---|
| Sponsor | Pfizer Inc. |
| Drug class | Data not available |
| Target | Data not available |
| Therapeutic area | Oncology |
| Phase | discontinued |
Mechanism of action
No molecular target, binding mechanism, or pharmacological details are available in the provided source data. The drug was terminated during Phase 1 development before sufficient clinical or preclinical data were published or disclosed. Without access to the original IND application, patent filings, or published research, the mechanism cannot be characterized.
Approved indications
Pipeline indications
- Advanced or Metastatic Solid Tumors — Phase 1
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PF-07329640 CI brief — competitive landscape report
- PF-07329640 updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI